by Fatemeh Rahmatabadi: This week’s journal club focuses on a study from Drugs in R&D (2024) aiming to assess the activity of trametinib against a panel of tumor cells from patients with AML
by Fatemeh Rahmatabadi Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylation. Enzenmüller et al. explore why B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells sometimes resist the BCL-2 inhibitor…
by Fatemeh Rahmatabadi This study by Hirosawa et al. investigates the effect of the p38 MAPK inhibitor SB202190 on acute myeloid leukemia (AML) cells. While p38 signaling is typically associated with stress responses and growth inhibition, treatment of AML cell…
by Fatemeh Rahmatabadi This article by Sosa et al. explores the biology of disseminated tumor cells (DTCs), which are central to cancer relapses and metastasis. DTCs can spread early during tumor development—even from non-invasive lesions—and persist in distant organs such…
by Fatemeh Rahmatabadi Acute myeloid leukemia (AML) is an aggressive blood cancer marked by the rapid expansion of immature myeloblasts. Despite progress in targeted therapies, resistance remains a major obstacle, especially in patients with mutations that impact the MAPK and…
by Fatemeh Rahmatabadi Acute myeloid leukemia (AML) is the most common myeloid cancer in adults, arising from hematopoietic stem cells and marked by a rapid proliferation of immature myeloblasts. Its genetic and clinical diversity complicates treatment. Key mutated genes include…